Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Real-World Clinical Outcomes of Severe, Treatment-Refractory Chronic Gvhd Patients Treated with Axatilimab Combination Therapies

Ayush V Peddireddi, Jean Caputo, Sarah A. Wall, Sumithira Vasu, Sam Penza, Kevin Ho, Vincent Esguerra, Benjamin Kaffenberger, Hannah Choe

Blood (2024) 144 (Supplement 1): 7362.

https://doi.org/10.1182/blood-2024-206425

Published: 2024

Journal Articles

Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study

Hannah Choe, Amandeep Salhotra, Nosha Farhadfar, Mi Kwon, Britnie Thomas, Vedran Radojcic, Chuan Tian, Shuyuan Lou, Daniel Wolff, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 98.

https://doi.org/10.1182/blood-2024-209965

Published: 2024

Journal Articles

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Blood (2024) 144 (Supplement 1): 384.

https://doi.org/10.1182/blood-2024-203344

Published: 2024

Journal Articles

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Mehrdad Abedi, Samer A. Srour, Amandeep Salhotra, Rasmus T. Hoeg, Edmund K. Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Robert Lowsky

Blood (2024) 144 (Supplement 1): 382.

https://doi.org/10.1182/blood-2024-204256

Published: 2024

Journal Articles

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Blood (2024) 144 (Supplement 1): 380.

https://doi.org/10.1182/blood-2024-204010

Published: 2024

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Journal Articles

Comparing Immune Reconstitution in Post-Transplant Cy Myeloablative Vs Reduced Intensity Transplants: Notable Trends in Monocyte Population

Manan Shah, Mandi Zhu, Rathan Kumar, Malith Karunasiri, Lotus Neidemire-Colley, Nicholas Yuhasz, Elizabeth Miller, Marcos de Lima, Parvathi Ranganathan, Hannah Choe

Blood (2024) 144 (Supplement 1): 7336.

https://doi.org/10.1182/blood-2024-201863

Published: 2024

Journal Articles

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 7303.

https://doi.org/10.1182/blood-2024-194146

Published: 2024

Journal Articles

Safety and Efficacy of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease (aGvHD) in Combination with Best Available Therapy: Results from a Multicenter, Randomized, Single-Blind, Proof-of-Concept, Phase 2 Stargaze Trial

Robert Zeiser, Hannah Choe, Holger Adelmann, Nader N. Youssef, Anastasia Eremeeva, François Collin, Yi-Bin Chen

Blood (2024) 144 (Supplement 1): 100.

https://doi.org/10.1182/blood-2024-198360

Published: 2024

Journal Articles

Bromodomain/Extra-Terminal Inhibition (BETi) and Ruxolitinib: Immune Profiling Insights from Human Samples in Acute Gvhd

Manan Shah, Rathan Kumar, Lotus Neidemire-Colley, Mandi Zhu, Nicholas Yuhasz, Malith Karunasiri, Parvathi Ranganathan, Hannah Choe

Blood (2024) 144 (Supplement 1): 4906.

https://doi.org/10.1182/blood-2024-199900

Published: 2024

Journal Articles

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2024-206559

Published: 2024

Journal Articles

A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults

Pooja Khandelwal, Lucille Langenberg, Nathan Luebbering, Kelly E. Lake, Abigail Butcher, Kylie Bota, Kristie N. Ramos, Cynthia Taggart, Hannah Choe, Sumithira Vasu, Ashley Teusink-Cross, Jane Koo, Gregory Wallace, Lindsey Romick-Rosendale, Miki Watanabe-Chailland, David B. Haslam, Adam Lane, Stella M. Davies

Blood (2024) 143 (12): 1181–1192.

https://doi.org/10.1182/blood.2023022865

Published: 2024

Includes: Supplemental data

Journal Articles

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Blood (2023) 142 (Supplement 1): 3576.

https://doi.org/10.1182/blood-2023-182300

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Journal Articles

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- Versus -Host-Disease Via Modulating the CXCR5/CXCL13 Axis

Rathan Kumar, Lotus Neidermire-Colley, Charlie Spencer, David Aslaner, Yandi Gao, Simran Surana, Matthew W Gorr, Katiri Snyder, Malith Karunasiri, Loren E Wold, Gideon Bollag, Ben Powell, Hannah Choe, Parvathi Ranganathan

Blood (2023) 142 (Supplement 1): 2047.

https://doi.org/10.1182/blood-2023-182354

Published: 2023

Journal Articles

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Blood (2023) 142 (Supplement 1): 779.

https://doi.org/10.1182/blood-2023-172955

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Blood (2023) 142 (Supplement 1): 776.

https://doi.org/10.1182/blood-2023-181900

Published: 2023

NARROW

Real-World Clinical Outcomes of Severe, Treatment-Refractory Chronic Gvhd Patients Treated with Axatilimab Combination Therapies

Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Comparing Immune Reconstitution in Post-Transplant Cy Myeloablative Vs Reduced Intensity Transplants: Notable Trends in Monocyte Population

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Bromodomain/Extra-Terminal Inhibition (BETi) and Ruxolitinib: Immune Profiling Insights from Human Samples in Acute Gvhd

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- Versus -Host-Disease Via Modulating the CXCR5/CXCL13 Axis

A Day 14 Endpoint for Acute Gvhd Clinical Trials

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only